Skip to main content

Joan Genescà Ferrer

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Joan Genescà Ferrer

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Chief Liver Unit.
Clinical director of Digestive Diseases.
Professor of Medicine of the UAB.

Projects

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEM APPROACHES

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 130472.5
Reference: DECISION_H2020-SC1-BHC2019
Duration: 01/04/2020 - 30/09/2025

Enfermedades hepáticas-Enfermedad crónica hepática avanzada y sus complicaciones.

IP: Joan Genescà Ferrer
Collaborators: Mònica Pons Delgado, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM18/00061
Duration: 01/01/2019 - 20/09/2021

EU Patient- cEntric clinicAl tRial pLatform - EU PEARL.

IP: Joan Genescà Ferrer
Collaborators: Santiago Pérez Hoyos, Anna Sanjuan Viaplana, Xavier Cañas Perea, Juan Espinosa Pereiro, Juan Manuel Pericàs Pulido, José Antonio Ramos Quiroga, Israel Molina Romero, Alex Sánchez Pla, Inmaculada Fuentes Camps, Elena de Sena Fernández, Adrián Sánchez Montalvá, Pol Ibañez Jimenez, Olga Sánchez- Maroto Carrizo, Gara Arteaga Henriquez, Jesus Manuel Rivera Esteban, Sergio Gabriel Muñoz Martínez, Navarro Villarreal, Clara, Janna Anthonina Slabbekoorn, Albert Barberà LLuis
Funding agency: The Innovative Medicines Initiative
Funding: 1987375
Reference: EU-PEARL_H2020_IMI2-2018
Duration: 01/11/2019 - 30/04/2023

Screening for liver fibrosis - population-based study across European countries

IP: Juan Manuel Pericàs Pulido
Collaborators: Joan Genescà Ferrer, Maria Francesca Cortese, Jesus Manuel Rivera Esteban, Laura Puente Ramo, Juan Bañares Sanchez
Funding agency: EUROPEAN COMMISSION
Funding: 172385.95
Reference: LIVERSCREEN_H2020SC1BHC2019
Duration: 01/01/2020 - 30/06/2025

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Marta Palau Requena

Marta Palau Requena

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
González Sánchez Alejandra

González Sánchez Alejandra

Predoctoral researcher
Microbiology
Read more
Rodrigo Maluje Juri

Rodrigo Maluje Juri

Predoctoral researcher
Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Marta Antonio Martín

Marta Antonio Martín

Predoctoral researcher
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.